title: An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution.
abstract: Reduced-intensity (RIT) conditioning regimens are gaining increased attention as a result of their advantages and efficacy. However, no data are available regarding whether these regimens improve patient quality of life (QoL). In our study, health-related QoL (HRQoL) was retrospectively assessed in 111 patients with hematological malignancies. Analysis of the Quality of Life Questionnaire indicated that 35 of the RIT patients were able to perform their normal work and returned to their baseline levels of function 2 to 3 months after transplantation. In the myeloablative (MA) group, only 24 patients were able to resume work, and these patients returned to their baseline levels of function 6 to 8 months after transplantation (68.6% vs. 40.0%, P = 0.004). Grade III-IV organ toxicity occurred in 20% of the RIT patients and in 52% of the MA patients (P = 0.001), and the cumulative incidences of grades III-IV acute graft-versus-host disease (GVHD) were 13.7% and 35.0% in RIT and MA patients, respectively (P = 0.015). In conclusion, the RIT conditioning regimens were well tolerated by the patients, with a low incidence of transplant-related mortality (TRM) and serious acute GVHD. In addition, these regimens minimized procedure-related toxicity, improved QoL and did not influence lymphocyte reconstitution; however, OS was similar for both regimens because the relapse rate was relatively increased in the RIT groups.
authors.affiliation: Department of Hematology (Key Department of Jiangsu Medicine), ZhongDa Hospital, Southeast University, Nanjing, China.
authors.forename: Zheng-Ping
authors.initials: ZP
authors.lastname: Yu
authors.forename: Jia-Hua
authors.initials: JH
authors.lastname: Ding
authors.forename: Bao-An
authors.initials: BA
authors.lastname: Chen
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Li
authors.forename: Bang-He
authors.initials: BH
authors.lastname: Ding
authors.forename: Jun
authors.initials: J
authors.lastname: Qian
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D019337:Hematologic Neoplasms / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D053208:Kaplan-Meier Estimate; D008171:Lung Diseases / Q000209:etiology; D008214:Lymphocytes / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D016016:Proportional Hazards Models; D011788:Quality of Life; D020127:Recovery of Function / Q000276:immunology / Q000502:physiology; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine
references.citation: N Engl J Med. 1975 Apr 17;292(16):832-43
references.pmid: 234595
references.citation: Bone Marrow Transplant. 2008 Feb;41(4):399-405
references.pmid: 17982493
references.citation: Bone Marrow Transplant. 2008 Dec;42(12):819-27
references.pmid: 18711345
references.citation: Blood. 2002 Aug 15;100(4):1201-7
references.pmid: 12149198
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1993-2003
references.pmid: 15774790
references.citation: J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
references.pmid: 8433390
references.citation: Blood. 2001 Feb 1;97(3):631-7
references.pmid: 11157478
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9387-93
references.pmid: 16314618
references.citation: Leuk Lymphoma. 2002 Jun;43(6):1159-67
references.pmid: 12152983
references.citation: Bone Marrow Transplant. 2005 May;35(10):1011-8
references.pmid: 15821768
references.citation: Semin Immunopathol. 2008 Dec;30(4):425-37
references.pmid: 18949477
references.citation: Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
references.pmid: 10758303
references.citation: Blood. 2004 Feb 15;103(4):1527-33
references.pmid: 14525770
references.citation: Blood. 1998 Feb 1;91(3):756-63
references.pmid: 9446633
references.citation: Br J Haematol. 1990 Mar;74(3):277-81
references.pmid: 2159315
references.citation: JAMA. 1993 Jul 7;270(1):57-60
references.pmid: 8510297
references.citation: Bone Marrow Transplant. 2004 May;33(9):881-9
references.pmid: 14990986
references.citation: Blood. 2006 Aug 1;108(3):836-46
references.pmid: 16597592
references.citation: Blood. 2001 Jun 1;97(11):3390-400
references.pmid: 11369628
references.citation: Blood. 2000 Sep 15;96(6):2062-8
references.pmid: 10979948
references.citation: Hematology Am Soc Hematol Educ Program. 2005;:151-5
references.pmid: 16304373
references.citation: Blood. 2002 Feb 1;99(3):1071-8
references.pmid: 11807015
references.citation: Br J Haematol. 2000 Mar;108(4):754-60
references.pmid: 10792280
references.citation: Blood. 1996 Nov 15;88(10):4063-71
references.pmid: 8916975
references.citation: Transplantation. 2002 Apr 15;73(7):1154-8
references.pmid: 11965050
references.citation: Leukemia. 2007 Jul;21(7):1387-94
references.pmid: 17410187
references.citation: Bone Marrow Transplant. 2003 Oct;32(7):703-7
references.pmid: 13130318
references.citation: Bone Marrow Transplant. 2005 Aug;36(4):343-8
references.pmid: 15968295
references.citation: Blood. 2002 Apr 1;99(7):2586-91
references.pmid: 11895797
references.citation: J Clin Oncol. 1998 Aug;16(8):2817-24
references.pmid: 9704734
references.citation: Curr Opin Oncol. 1999 Mar;11(2):87-95
references.pmid: 10188072
references.citation: Bone Marrow Transplant. 2004 Oct;34(8):729-38
references.pmid: 15354204
references.citation: Blood. 1997 Jun 15;89(12):4531-6
references.pmid: 9192777